Success Story: Improving Medication Adherence Through EHR Data and Digital Health Design: NIW Approval Secured for a Chinese Biostatistics Researcher
Client’s Testimonial:
"Thank you so much for your message and for all of your help throughout this process!! I’m very excited and grateful to hear that my I-140 NIW has been approved!! I truly appreciate all of your guidance, support, and responsiveness during the preparation and filing process. It has been a pleasure working with your team.”
On May 27th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Data Analyst in the field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: Senior Data Analyst
Country of Origin: China
State of Residence at the Time of Filing: New York
Approval Notice Date: May 27th, 2026
Processing Time: 1 year, 1 month, 27 days (Premium Processing Requested)
Case Summary:
Medication adherence remains a major challenge in chronic disease management, affecting patient outcomes, healthcare costs, and care quality. For this Chinese biostatistics researcher, the proposed endeavor focused on using digital design and electronic health record data to improve medication adherence among patients with chronic conditions. At the time of filing, she was employed as a senior data analyst at a U.S. medical research institution, where her work involved clinical and operational data, statistical analysis, predictive modeling, patient-level adherence research, and data-driven healthcare quality improvement.
Research Contributions in Biostatistics
The client addressed this healthcare challenge through biostatistics, digital health design, artificial intelligence, and electronic health record (EHR) data. Her work examined AI-generated discharge summaries, EHR-based interventions for hypertension medication adherence, linked prescription and pharmacy data, and methods for measuring adherence patterns. These contributions support clearer patient communication, stronger chronic disease management, and more effective use of healthcare data.
Academic Contributions and Recognition
At the time of filing, the client had authored 8 peer-reviewed journal articles and 8 abstracts, with 77 citations and at least 2 peer reviews for an authoritative journal in her field. Two publications were especially notable, with one ranked within the top 0.01% of Clinical Medicine papers for its publication year and another ranked within the top 10%.
The petition demonstrated her significance through peer-reviewed publications in highly ranked venues, citation impact, peer review service, National Heart, Lung, and Blood Institute (NHLBI)-supported research, recommendation letters, and documented reliance on her findings by independent researchers. Her work had influenced studies on AI in healthcare, patient-friendly clinical communication, medication nonadherence, adherence assessment, and EHR-based chronic disease management.
Expert Endorsements
Recommendation letters emphasized the client’s expertise in biostatistics, digital health research, EHR-based analysis, and medication adherence studies.
One expert stated:
“The importance of [client]’s research to addressing low antihypertensive medication adherence and reducing preventable cardiovascular events is evident, given the breakthroughs that her research has fostered in these areas and the field of biostatistics more generally.”
Together with her publication record, citation impact, peer review service, highly ranked publication venues, and independent reliance on her findings, this expert support strengthened the petition’s argument that her work is significant to biostatistics and healthcare delivery.
NIW Approval and Outlook
The I-140 NIW petition was filed on March 31st, 2025, later upgraded to Premium Processing, and approved on May 27th, 2026. The approval recognized the national importance of the client’s work in biostatistics, particularly her research on digital health design, EHR data, medication adherence, and chronic disease management.
This outcome supports the client’s continued efforts to advance data-driven healthcare research, improve medication adherence, and contribute to more efficient and patient-centered healthcare delivery in the United States.